Spiramycin adipate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 574490

CAS#: 68880-55-7 (adipate)

Description: Spiramycin adipate is an antibiotic that is used to study multidrug resistance of Strenotrophomonas maltophilia.

Chemical Structure

img
Spiramycin adipate
CAS# 68880-55-7 (adipate)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 574490
Name: Spiramycin adipate
CAS#: 68880-55-7 (adipate)
Chemical Formula: C49H84N2O18
Exact Mass: 0.00
Molecular Weight: 989.210
Elemental Analysis: C, 59.50; H, 8.56; N, 2.83; O, 29.11

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 8025-81-8 (free base)   24916-52-7 (III)   67724-08-7 (Embonate)   68880-55-7 (adipate)    

Synonym: Spiramycin adipate; Spiramycin, Hexanedioate (salt); Suanovil

IUPAC/Chemical Name: 2-((4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-(((2S,3R,4R,5S,6R)-5-(((2S,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-10-(((5S,6R)-5-(dimethylamino)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-7-yl)acetaldehyde adipate

InChi Key: PLQDGTZICFBBSO-DPUAUXBSSA-N

InChi Code: InChI=1S/C43H74N2O14.C6H10O4/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34;7-5(8)3-1-2-4-6(9)10/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3;1-4H2,(H,7,8)(H,9,10)/b13-12+,16-14+;/t24-,25-,26-,27-,28+,29+,30+,31-,32+,34?,35+,36-,37-,38-,39+,40+,41+,42+,43-;/m1./s1

SMILES Code: CO[C@H]1[C@@H](CC(O[C@@H](C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]1O[C@@H]2O[C@@H]([C@H]([C@H](N(C)C)[C@H]2O)O[C@H]3C[C@@](O)([C@H]([C@@H](O3)C)O)C)C)CC=O)C)OC4CC[C@H](N(C)C)[C@H](O4)C)C)=O)O.OC(CCCCC(O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Spiramycin adipate is effective against gram-positive aerobic pathogens, N. gonorrhoeae, and staphylococci.
In vitro activity: Spiramycin has potential to be repurposed as a topical anti-inflammatory treatment. In lipopolysaccharide (LPS)-stimulated RAW 264.7 cells, spiramycin reduced levels of inflammatory markers like nitric oxide, IL-1β, and IL-6. It also inhibited the expression of NO synthase and blocked key signaling pathways involved in inflammation. Reference: Molecules. 2022 May 17;27(10):3202. https://pubmed.ncbi.nlm.nih.gov/35630676/
In vivo activity: Spiramycin has potential in anti-obesity treatment. Spiramycin effectively attenuated high fat diet (HFD)-induced obesity and hepatic steatosis by inhibiting adipogenesis in obese mice. HFD-induced obese mice administered spiramycin had substantial decreases in body weight gain, serum leptin levels, adipose tissue mass, and hepatic lipid accumulation. The decreased levels of GPT and GOT in mice serum indicated that spiramycin attenuated hepatic injury caused by HFD. Reference: PLoS One. 2016 Jul 11;11(7):e0158632. https://pubmed.ncbi.nlm.nih.gov/27398599/

Preparing Stock Solutions

The following data is based on the product molecular weight 989.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Yagiz Aghayarov O, Bayar Muluk N, Vejselova Sezer C, Kutlu HM, Cingi C. Evaluation of spiramycin for topical applications: a cell culture study. Eur Rev Med Pharmacol Sci. 2023 Mar;27(2 Suppl):44-50. doi: 10.26355/eurrev_202303_31701. PMID: 36971220. 2. Kang JK, Kang HK, Hyun CG. Anti-Inflammatory Effects of Spiramycin in LPS-Activated RAW 264.7 Macrophages. Molecules. 2022 May 17;27(10):3202. doi: 10.3390/molecules27103202. PMID: 35630676; PMCID: PMC9143090. 3. Kim MO, Ryu HW, Choi JH, Son TH, Oh SR, Lee HS, Yuk HJ, Cho S, Kang JS, Lee CW, Lee J, Lee CK, Hong ST, Lee SU. Anti-Obesity Effects of Spiramycin In Vitro and In Vivo. PLoS One. 2016 Jul 11;11(7):e0158632. doi: 10.1371/journal.pone.0158632. PMID: 27398599; PMCID: PMC4939947. 4. Chew WK, Segarra I, Ambu S, Mak JW. Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1762-8. doi: 10.1128/AAC.05183-11. Epub 2012 Jan 23. PMID: 22271863; PMCID: PMC3318357.
In vitro protocol: 1. Yagiz Aghayarov O, Bayar Muluk N, Vejselova Sezer C, Kutlu HM, Cingi C. Evaluation of spiramycin for topical applications: a cell culture study. Eur Rev Med Pharmacol Sci. 2023 Mar;27(2 Suppl):44-50. doi: 10.26355/eurrev_202303_31701. PMID: 36971220. 2. Kang JK, Kang HK, Hyun CG. Anti-Inflammatory Effects of Spiramycin in LPS-Activated RAW 264.7 Macrophages. Molecules. 2022 May 17;27(10):3202. doi: 10.3390/molecules27103202. PMID: 35630676; PMCID: PMC9143090.
In vivo protocol: 1. Kim MO, Ryu HW, Choi JH, Son TH, Oh SR, Lee HS, Yuk HJ, Cho S, Kang JS, Lee CW, Lee J, Lee CK, Hong ST, Lee SU. Anti-Obesity Effects of Spiramycin In Vitro and In Vivo. PLoS One. 2016 Jul 11;11(7):e0158632. doi: 10.1371/journal.pone.0158632. PMID: 27398599; PMCID: PMC4939947. 2. Chew WK, Segarra I, Ambu S, Mak JW. Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1762-8. doi: 10.1128/AAC.05183-11. Epub 2012 Jan 23. PMID: 22271863; PMCID: PMC3318357.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x